{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:45:04Z","timestamp":1790163904191,"version":"4.1.0"},"reference-count":135,"publisher":"Portland Press Ltd.","issue":"16","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,15]]},"abstract":"<jats:p>Anorexia and metabolic alterations are the main components of the cachectic syndrome. Glucose intolerance, fat depletion, muscle protein catabolism and other alterations are involved in the development of cancer cachexia, a multi-organ syndrome. Nutritional approach strategies are not satisfactory in reversing the cachectic syndrome. The aim of the present review is to deal with the recent therapeutic targeted approaches that have been designed to fight and counteract wasting in cancer patients. Indeed, some promising targeted therapeutic approaches include ghrelin agonists, selective androgen receptor agonists, \u03b2-blockers and antimyostatin peptides. However, a multi-targeted approach seems absolutely essential to treat patients affected by cancer cachexia. This approach should not only involve combinations of drugs but also nutrition and an adequate program of physical exercise, factors that may lead to a synergy, essential to overcome the syndrome. This may efficiently reverse the metabolic changes described above and, at the same time, ameliorate the anorexia. Defining this therapeutic combination of drugs\/nutrients\/exercise is an exciting project that will stimulate many scientific efforts. Other aspects that will, no doubt, be very important for successful treatment of cancer wasting will be an optimized design of future clinical trials, together with a protocol for staging cancer patients in relation to their degree of cachexia. This will permit that nutritional\/metabolic\/pharmacological support can be started early in the course of the disease, before severe weight loss occurs. Indeed, timing is crucial and has to be taken very seriously when applying the therapeutic approach.<\/jats:p>","DOI":"10.1042\/bcj20170032","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T20:11:03Z","timestamp":1501186263000},"page":"2663-2678","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Novel targeted therapies for cancer cachexia"],"prefix":"10.1042","volume":"474","author":[{"given":"Josep M.","family":"Argil\u00e9s","sequence":"first","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Diagonal 643, Barcelona 08028, Spain"},{"name":"Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"L\u00f3pez-Soriano","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Diagonal 643, Barcelona 08028, Spain"},{"name":"Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Stemmler","sequence":"additional","affiliation":[{"name":"BS Nutrition Centre, 08195 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00edlvia","family":"Busquets","sequence":"additional","affiliation":[{"name":"Cancer Research Group, Departament de Bioqu\u00edmica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Diagonal 643, Barcelona 08028, Spain"},{"name":"Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2017,7,27]]},"reference":[{"key":"2021112216472296200_BCJ-2017-0032CC1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/182872","article-title":"Nonmuscle tissues contribution to cancer cachexia","volume":"2015","author":"Argil\u00e9s","year":"2015","journal-title":"Mediators Inflamm."},{"key":"2021112216472296200_BCJ-2017-0032CC2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.clnu.2016.05.010","article-title":"The 2015 ESPEN Sir David Cuthbertson lecture: inflammation as the driving force of muscle wasting in cancer","volume":"36","author":"Argil\u00e9s","year":"2017","journal-title":"Clin. Nutr."},{"key":"2021112216472296200_BCJ-2017-0032CC3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin. Nutr."},{"key":"2021112216472296200_BCJ-2017-0032CC4","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","article-title":"Cancer cachexia: understanding the molecular basis","volume":"14","author":"Argil\u00e9s","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC5","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.clnu.2013.01.004","article-title":"A new look at an old drug for the treatment of cancer cachexia: megestrol acetate","volume":"32","author":"Argil\u00e9s","year":"2013","journal-title":"Clin. Nutr."},{"key":"2021112216472296200_BCJ-2017-0032CC6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.clnu.2010.06.003","article-title":"Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia","volume":"29","author":"Busquets","year":"2010","journal-title":"Clin. Nutr."},{"key":"2021112216472296200_BCJ-2017-0032CC7","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2147\/DDDT.S62176","article-title":"Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state","volume":"8","author":"Jang","year":"2014","journal-title":"Drug Des. Devel. Ther."},{"key":"2021112216472296200_BCJ-2017-0032CC8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.clnu.2005.05.001","article-title":"An epidemiological evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or metastatic cancer","volume":"24","author":"Segura","year":"2005","journal-title":"Clin. Nutr."},{"key":"2021112216472296200_BCJ-2017-0032CC9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/157339910791658871","article-title":"Cardiovascular and metabolic effects of ghrelin","volume":"6","author":"Tesauro","year":"2010","journal-title":"Curr. Diabetes Rev."},{"key":"2021112216472296200_BCJ-2017-0032CC10","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1517\/14712598.2013.727390","article-title":"The potential of ghrelin in the treatment of cancer cachexia","volume":"13","author":"Argil\u00e9s","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"2021112216472296200_BCJ-2017-0032CC11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S0006-291X(02)03028-0","article-title":"Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells","volume":"301","author":"Hanada","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112216472296200_BCJ-2017-0032CC12","first-page":"1393","article-title":"Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia","volume":"28","author":"Wang","year":"2006","journal-title":"Int. J. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC13","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1210\/en.2007-0016","article-title":"Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia","volume":"148","author":"DeBoer","year":"2007","journal-title":"Endocrinology"},{"key":"2021112216472296200_BCJ-2017-0032CC14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1210\/en.2007-0828","article-title":"Ghrelin prevents cisplatin-induced mechanical hyperalgesia and cachexia","volume":"149","author":"Garcia","year":"2008","journal-title":"Endocrinology"},{"key":"2021112216472296200_BCJ-2017-0032CC15","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1210\/en.2010-0061","article-title":"Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia","volume":"151","author":"Yakabi","year":"2010","journal-title":"Endocrinology"},{"key":"2021112216472296200_BCJ-2017-0032CC16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1470-2045(14)71154-4","article-title":"Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials","volume":"16","author":"Garcia","year":"2015","journal-title":"Lancet Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/jco.2015.33.29_suppl.175","article-title":"Anamorelin in patients with advanced non-small cell lung cancer and cachexia: results from the phase III studies ROMANA 1 and 2","volume":"33","author":"Temel","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC18","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","article-title":"Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials","volume":"17","author":"Temel","year":"2016","journal-title":"Lancet Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/jco.2016.34.26_suppl.203","article-title":"Efficacy of anamorelin in cachectic patients with non-small cell lung cancer (NSCLC) and low BMI (&lt;20 kg\/m2): Post-hoc analysis of two phase III studies","volume":"34","author":"Currow","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC20","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","article-title":"Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial","volume":"24","author":"Takayama","year":"2016","journal-title":"Support. Care Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC21","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT01614990, Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia; June 5, 2012, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT01614990"},{"key":"2021112216472296200_BCJ-2017-0032CC22","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/j.clnme.2012.07.004","article-title":"Randomized study of the efficacy and safety of SUN11031 (synthetic human ghrelin) in cachexia associated with chronic obstructive pulmonary disease","volume":"7","author":"Levinson","year":"2012","journal-title":"e-SPEN J."},{"key":"2021112216472296200_BCJ-2017-0032CC23","doi-asserted-by":"publisher","first-page":"e4774","DOI":"10.1371\/journal.pone.0004774","article-title":"Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice","volume":"4","author":"Weyermann","year":"2009","journal-title":"PLoS ONE"},{"key":"2021112216472296200_BCJ-2017-0032CC24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13539-011-0039-1","article-title":"The orally active melanocortin-4 receptor antagonist BL-6020\/979: a promising candidate for the treatment of cancer cachexia","volume":"2","author":"Dallmann","year":"2011","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC25","doi-asserted-by":"publisher","first-page":"E1000","DOI":"10.1152\/ajpendo.90252.2008","article-title":"Neural control of the anorexia-cachexia syndrome","volume":"295","author":"Laviano","year":"2008","journal-title":"AJP Endocrinol. Metab."},{"key":"2021112216472296200_BCJ-2017-0032CC26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/MPH.0b013e3181864a5e","article-title":"The effect of cyproheptadine hydrochloride (periactin) and megestrol acetate (megace) on weight in children with cancer\/treatment-related cachexia","volume":"30","author":"Couluris","year":"2008","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC27","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/1097-0142(19900615)65:12<2657::AID-CNCR2820651210>3.0.CO;2-S","article-title":"A controlled trial of cyproheptadine in cancer patients with anorexia and\/or cachexia","volume":"65","author":"Kardinal","year":"1990","journal-title":"Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC28","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1186\/1471-2407-14-578","article-title":"Macrophage inhibitory cytokine 1 (MIC-1\/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma","volume":"14","author":"Wang","year":"2014","journal-title":"BMC Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/ijo.2015.242","article-title":"Anorexia\u2013cachexia and obesity treatment may be two sides of the same coin: role of the TGF-b superfamily cytokine MIC-1\/GDF15","volume":"40","author":"Tsai","year":"2016","journal-title":"Int. J. Obes."},{"key":"2021112216472296200_BCJ-2017-0032CC30","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-4650","article-title":"Abstract 4650: from bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia","volume":"73","author":"Vigano","year":"2014","journal-title":"Cancer Res."},{"key":"2021112216472296200_BCJ-2017-0032CC31","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.7314\/APJCP.2014.15.15.6047","article-title":"Weight loss correlates with macrophage inhibitory cytokine-1 expression and might influence outcome in patients with advanced esophageal squamous cell carcinoma","volume":"15","author":"Lu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"2021112216472296200_BCJ-2017-0032CC32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/gut.2004.047563","article-title":"Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial","volume":"54","author":"Gordon","year":"2005","journal-title":"Gut"},{"key":"2021112216472296200_BCJ-2017-0032CC33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1089\/jpm.2012.0146","article-title":"The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study","volume":"15","author":"Yennurajalingam","year":"2012","journal-title":"J. Palliat. Med."},{"key":"2021112216472296200_BCJ-2017-0032CC34","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT01127386, Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome; May 12, 2010, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01127386"},{"key":"2021112216472296200_BCJ-2017-0032CC35","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT00201812, Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors, September 12, 2005, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00201812"},{"key":"2021112216472296200_BCJ-2017-0032CC36","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1200\/JCO.2005.04.2838","article-title":"Assessment of tumor necrosis factor \u03b1 blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients","volume":"24","author":"Monk","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC38","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1007\/s00520-013-1878-4","article-title":"Interleukin-6 but not tumour necrosis factor-\u03b1 predicts survival in patients with advanced cancer","volume":"21","author":"Suh","year":"2013","journal-title":"Support. Care Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC39","doi-asserted-by":"publisher","first-page":"e102436","DOI":"10.1371\/journal.pone.0102436","article-title":"Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer","volume":"9","author":"Ando","year":"2014","journal-title":"PLoS ONE"},{"key":"2021112216472296200_BCJ-2017-0032CC40","doi-asserted-by":"crossref","unstructured":"Rigas, J.R., Schuster, M., Orlov, S.V., Milovanovic, B., Prabhash, K., Smith, J.T. and the ALD5 study group. (2010) Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial. 2010 ASCO Annual Meeting, Chicago IL, U.S.A., 4\u20138 June 2010, Abstract 7622","DOI":"10.1200\/jco.2010.28.15_suppl.7622"},{"key":"2021112216472296200_BCJ-2017-0032CC41","doi-asserted-by":"crossref","unstructured":"Schuster, M., Rigas, J.R., Orlov, S.V., Milovanovic, B., Prabhash, K., Smith, J.T. and the ALD5 study group. ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial. 2010 ASCO Annual Meeting, Chicago IL, U.S.A., 4\u20138 June 2010, Abstract 7631","DOI":"10.1200\/jco.2010.28.15_suppl.7631"},{"key":"2021112216472296200_BCJ-2017-0032CC42","doi-asserted-by":"publisher","first-page":"214.e1","DOI":"10.1016\/j.clml.2014.12.008","article-title":"Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I","volume":"15","author":"Mesa","year":"2015","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"2021112216472296200_BCJ-2017-0032CC43","unstructured":"Chasen, M. (2013) Phase II Data on OHR\/AVR118 in Advanced Cancer Patients With Cachexia. Int. Cachexia Conf. Kobe, Japan"},{"key":"2021112216472296200_BCJ-2017-0032CC44","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jamda.2010.02.012","article-title":"Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia\/cachexia","volume":"12","author":"Chasen","year":"2011","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"2021112216472296200_BCJ-2017-0032CC45","doi-asserted-by":"publisher","first-page":"e0132786","DOI":"10.1371\/journal.pone.0132786","article-title":"TGF-\u03b2 blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia","volume":"10","author":"Greco","year":"2015","journal-title":"PLoS ONE"},{"key":"2021112216472296200_BCJ-2017-0032CC46","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-\u03b2 mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat. Med."},{"key":"2021112216472296200_BCJ-2017-0032CC47","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.febslet.2004.05.066","article-title":"Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats","volume":"569","author":"Figueras","year":"2004","journal-title":"FEBS Lett."},{"key":"2021112216472296200_BCJ-2017-0032CC48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.drudis.2008.10.010","article-title":"Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity","volume":"14","author":"Argil\u00e9s","year":"2009","journal-title":"Drug Discov. Today"},{"key":"2021112216472296200_BCJ-2017-0032CC49","first-page":"471","article-title":"Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect","volume":"16","author":"Busquets","year":"2005","journal-title":"Int. J. Mol. Med."},{"key":"2021112216472296200_BCJ-2017-0032CC50","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3892\/or.2012.1928","article-title":"Serum interleukin-15 levels in cancer patients with cachexia","volume":"28","author":"Mart\u00ednez-Hern\u00e1ndez","year":"2012","journal-title":"Oncol. Rep."},{"key":"2021112216472296200_BCJ-2017-0032CC51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/1097-0215(20000701)87:1&lt;95::AID-IJC14&gt;3.0.CO;2-D","article-title":"Effect of the specific cyclooxygenase-2 inhibitor meloxicam on tumour growth and cachexia in a murine model","volume":"87","author":"Hussey","year":"2000","journal-title":"Int. J. Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC52","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00109-009-0547-z","article-title":"Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia","volume":"88","author":"Mantovani","year":"2010","journal-title":"J. Mol. Med."},{"key":"2021112216472296200_BCJ-2017-0032CC53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/0269216312441382","article-title":"Non-steroidal anti-inflammatory drugs for the treatment of cancer cachexia: a systematic review","volume":"27","author":"Reid","year":"2013","journal-title":"Palliat. Med."},{"key":"2021112216472296200_BCJ-2017-0032CC54","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s13539-014-0153-y","article-title":"Formoterol in the treatment of experimental cancer cachexia: effects on heart function","volume":"5","author":"Toledo","year":"2014","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC55","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1158\/0008-5472.CAN-04-0425","article-title":"Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting","volume":"64","author":"Busquets","year":"2004","journal-title":"Cancer Res."},{"key":"2021112216472296200_BCJ-2017-0032CC56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5640\/insc.01011","article-title":"Formoterol may activate rat muscle regeneration during cancer cachexia","volume":"1","author":"Ametller","year":"2011","journal-title":"Insciences J."},{"key":"2021112216472296200_BCJ-2017-0032CC57","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/ijc.29930","article-title":"Complete reversal of muscle wasting in experimental cancer cachexia: additive effects of activin type II receptor inhibition and \u03b2-2 agonist","volume":"138","author":"Toledo","year":"2016","journal-title":"Int. J. Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC58","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00520-013-2081-3","article-title":"Phase I\/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy","volume":"22","author":"Greig","year":"2014","journal-title":"Support. Care Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC59","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cyto.2005.10.002","article-title":"Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine","volume":"32","author":"Kanzaki","year":"2005","journal-title":"Cytokine"},{"key":"2021112216472296200_BCJ-2017-0032CC60","doi-asserted-by":"publisher","first-page":"43202","DOI":"10.18632\/oncotarget.6439","article-title":"Combination of exercise training and erythropoietin prevents cancer-induced muscle alterations","volume":"6","author":"Pin","year":"2015","journal-title":"Oncotarget"},{"key":"2021112216472296200_BCJ-2017-0032CC61","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S1388-9842(00)00146-X","article-title":"The effects of enalapril-digoxin-diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia","volume":"3","author":"Adigun","year":"2001","journal-title":"Eur. J. Heart Fail."},{"key":"2021112216472296200_BCJ-2017-0032CC62","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/ijc.28128","article-title":"Inhibition of the renin-angiotensin system improves physiological outcomes in mice with mild or severe cancer cachexia","volume":"133","author":"Murphy","year":"2013","journal-title":"Int. J. Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC63","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/eurheartj\/eht302","article-title":"Prevention of liver cancer cachexia-induced cardiac wasting and heart failure","volume":"35","author":"Springer","year":"2014","journal-title":"Eur. Heart J."},{"key":"2021112216472296200_BCJ-2017-0032CC64","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s13539-012-0072-8","article-title":"Evidence for an effect of ACE inhibitors on cancer cachexia","volume":"3","author":"Schanze","year":"2012","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.lfs.2016.04.029","article-title":"Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia","volume":"154","author":"Sukumaran","year":"2016","journal-title":"Life Sci."},{"key":"2021112216472296200_BCJ-2017-0032CC66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/642848","article-title":"Combination of telmisartan with cisplatin controls oral cancer cachexia in rats","volume":"2013","author":"Patel","year":"2013","journal-title":"BioMed Res. Int."},{"key":"2021112216472296200_BCJ-2017-0032CC67","first-page":"S_513","article-title":"Abstract 5249: telmisartan manifests powerful anti-inflammatory effects beyond class effects of angiotensin II type 1 blocker by inhibiting tumor necrosis factor \u03b1-induced interleukin 6 expressions through peroxisome proliferator activated receptor\u03b3 activation","volume":"118","author":"Ichiki","year":"2016","journal-title":"Circulation"},{"key":"2021112216472296200_BCJ-2017-0032CC68","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/jcsm.12136","article-title":"ACT-ONE - ACTION at last on cancer cachexia by adapting a novel action \u03b2-blocker","volume":"7","author":"Lainscak","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC69","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/jcsm.12126","article-title":"Espindolol for the treatment and prevention of cachexia in patients with stage III\/IV non-small cell lung cancer or colorectal cancer: a randomized, double-blind, placebo-controlled, international multicentre phase II study (the ACT-ONE trial)","volume":"7","author":"Stewart Coats","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC70","unstructured":"Bhattacharyya, G.S. (2015) Vicus Therapeutics Announces Safety and Survival Benefit of VT-122 in Combination with Anti-Cancer Therapies for Advanced Liver and Pancreatic Cancers"},{"key":"2021112216472296200_BCJ-2017-0032CC71","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","article-title":"Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial","volume":"14","author":"Dobs","year":"2013","journal-title":"Lancet Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC72","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11912-016-0522-0","article-title":"Study design and rationale for the phase 3 clinical development program of enobosarm, a selective androgen receptor modulator, for the prevention and treatment of muscle wasting in cancer patients (POWER trials)","volume":"18","author":"Crawford","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"2021112216472296200_BCJ-2017-0032CC73","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2217\/fon.13.273","article-title":"Enobosarm (GTx-024, S-22): a potential treatment for cachexia","volume":"10","author":"Srinath","year":"2014","journal-title":"Future Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC74","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/1471-2474-15-291","article-title":"Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hindlimb immobilization","volume":"15","author":"Blanqu\u00e9","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"2021112216472296200_BCJ-2017-0032CC75","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT01397370, Multiple Ascending Dose Study of GLPG0492 in Healthy Subjects, July 18, 2011, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01397370"},{"key":"2021112216472296200_BCJ-2017-0032CC76","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00000658-199209000-00007","article-title":"Growth hormone and insulin reverse net whole body and skeletal muscle protein catabolism in cancer patients","volume":"216","author":"Wolf","year":"1992","journal-title":"Ann. Surg."},{"key":"2021112216472296200_BCJ-2017-0032CC77","first-page":"5483","article-title":"Growth hormone administration preserves lean body mass in sarcoma-bearing rats treated with doxorubicin","volume":"53","author":"Ng","year":"1993","journal-title":"Cancer Res."},{"key":"2021112216472296200_BCJ-2017-0032CC78","first-page":"127","article-title":"Is there a relationship between the growth hormone dose and tumoral or cardiovascular complications?","volume":"196","author":"Le Bouc","year":"2012","journal-title":"Bull. Acad. Natl Med."},{"key":"2021112216472296200_BCJ-2017-0032CC79","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT01388920, Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting, July 5, 2011, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01388920"},{"key":"2021112216472296200_BCJ-2017-0032CC80","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.archger.2010.10.004","article-title":"MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study","volume":"53","author":"Adunsky","year":"2011","journal-title":"Arch. Gerontol. Geriatr."},{"key":"2021112216472296200_BCJ-2017-0032CC81","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT00975104 , AMG 745 in Subjects With Age-associated Muscle Loss, September 10, 2009, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00975104"},{"key":"2021112216472296200_BCJ-2017-0032CC82","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT00755638, A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 (ActRIIB-IgG1) in Healthy Postmenopausal Volunteers, September 17, 2008, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00755638"},{"key":"2021112216472296200_BCJ-2017-0032CC83","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13539-013-0123-9","article-title":"Abstracts of the 7th cachexia conference, Kobe\/Osaka, Japan, December 9\u201311, 2013","volume":"4","author":"[No authors listed]","year":"2013","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC84","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"2021112216472296200_BCJ-2017-0032CC85","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2021112216472296200_BCJ-2017-0032CC86","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT01505530, A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer, January 4, 2012, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01505530"},{"key":"2021112216472296200_BCJ-2017-0032CC87","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT01963598 , Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia, October 11, 2013, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01963598"},{"key":"2021112216472296200_BCJ-2017-0032CC88","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/0014-5793(94)80290-4","article-title":"Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats","volume":"338","author":"Llovera","year":"1994","journal-title":"FEBS Lett."},{"key":"2021112216472296200_BCJ-2017-0032CC89","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.drudis.2007.10.008","article-title":"Novel approaches to the treatment of cachexia","volume":"13","author":"Argil\u00e9s","year":"2008","journal-title":"Drug Discov. Today"},{"key":"2021112216472296200_BCJ-2017-0032CC90","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/jcsm.12050","article-title":"Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting","volume":"7","author":"Penna","year":"2016","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC91","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12032-015-0538-6","article-title":"Combined treatment of carfilzomib and z-VAD-fmk inhibits skeletal proteolysis and apoptosis and ameliorates cancer cachexia","volume":"32","author":"Wang","year":"2015","journal-title":"Med. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC92","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ijcard.2012.09.074","article-title":"The effects of phosphodiesterase 5 inhibition on hemodynamics, functional status and survival in advanced heart failure and pulmonary hypertension: a case-control study","volume":"168","author":"Reichenbach","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2021112216472296200_BCJ-2017-0032CC93","unstructured":"Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer - Full Text View - ClinicalTrials.gov"},{"key":"2021112216472296200_BCJ-2017-0032CC94","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12885-016-2424-9","article-title":"Metformin treatment modulates the tumour-induced wasting effects in muscle protein metabolism minimising the cachexia in tumour-bearing rats","volume":"16","author":"Oliveira","year":"2016","journal-title":"BMC Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC95","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s13539-012-0097-z","article-title":"Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis","volume":"4","author":"Scott","year":"2013","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC96","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.trsl.2013.11.006","article-title":"Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks","volume":"163","author":"Rinaldi","year":"2014","journal-title":"Transl. Res."},{"key":"2021112216472296200_BCJ-2017-0032CC97","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ijcard.2013.04.150","article-title":"Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia","volume":"168","author":"Palus","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"2021112216472296200_BCJ-2017-0032CC98","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/ismej.2015.209","article-title":"Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia","volume":"10","author":"Bindels","year":"2016","journal-title":"ISME J."},{"key":"2021112216472296200_BCJ-2017-0032CC99","doi-asserted-by":"publisher","first-page":"e26425","DOI":"10.1002\/pbc.26425","article-title":"Neuroblastoma causes alterations of the intestinal microbiome, gut hormones, inflammatory cytokines, and bile acid composition","volume":"64","author":"Castellani","year":"2017","journal-title":"Pediatr. Blood Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC100","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/nm.4093","article-title":"Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia","volume":"22","author":"Fukawa","year":"2016","journal-title":"Nat. Med."},{"key":"2021112216472296200_BCJ-2017-0032CC101","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1007\/s10147-016-1025-6","article-title":"Nutritional care of cancer patients: a survey on patients\u2019 needs and medical care in reality","volume":"22","author":"Maschke","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC102","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.nut.2014.12.001","article-title":"Nutritional approaches in cancer: relevance of individualized counseling and supplementation","volume":"31","author":"Ravasco","year":"2015","journal-title":"Nutrition"},{"key":"2021112216472296200_BCJ-2017-0032CC103","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.appet.2015.04.049","article-title":"Nutrition therapy in cachectic cancer patients. The tight caloric control (TiCaCo) pilot trial","volume":"91","author":"De Waele","year":"2015","journal-title":"Appetite"},{"key":"2021112216472296200_BCJ-2017-0032CC104","doi-asserted-by":"publisher","first-page":"e108687","DOI":"10.1371\/journal.pone.0108687","article-title":"Nutritional advice in older patients at risk of malnutrition during treatment for chemotherapy: a two-year randomized controlled trial","volume":"9","author":"Bourdel-Marchasson","year":"2014","journal-title":"PLoS ONE"},{"key":"2021112216472296200_BCJ-2017-0032CC105","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1136\/gut.52.10.1479","article-title":"Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial","volume":"52","author":"Fearon","year":"2003","journal-title":"Gut"},{"key":"2021112216472296200_BCJ-2017-0032CC106","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2005.04.5724","article-title":"Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia","volume":"24","author":"Fearon","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC107","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/0269216311418709","article-title":"A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project","volume":"26","author":"Ries","year":"2012","journal-title":"Palliat. Med."},{"key":"2021112216472296200_BCJ-2017-0032CC108","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1200\/JCO.2004.06.024","article-title":"An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a north central cancer treatment group and national cancer institute of Canada collaborative effort","volume":"22","author":"Jatoi","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC109","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s00520-006-0153-3","article-title":"Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. effects on nutritional and inflammatory status: a phase II trial","volume":"15","author":"Read","year":"2007","journal-title":"Support. Care Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC110","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/SLA.0b013e31819a4789","article-title":"Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: results of a double-blinded randomized controlled trial","volume":"249","author":"Ryan","year":"2009","journal-title":"Ann. Surg."},{"key":"2021112216472296200_BCJ-2017-0032CC111","doi-asserted-by":"publisher","first-page":"E1409","DOI":"10.1152\/ajpendo.90530.2008","article-title":"Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by \u03b2-hydroxy-\u03b2-methylbutyrate","volume":"295","author":"Eley","year":"2008","journal-title":"AJP Endocrinol. Metab."},{"key":"2021112216472296200_BCJ-2017-0032CC112","doi-asserted-by":"publisher","first-page":"E923","DOI":"10.1152\/ajpendo.00314.2007","article-title":"Signaling pathways initiated by \u03b2-hydroxy-\u03b2-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli","volume":"293","author":"Eley","year":"2007","journal-title":"AJP Endocrinol. Metab."},{"key":"2021112216472296200_BCJ-2017-0032CC113","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.bbamcr.2008.12.017","article-title":"\u03b2-hydroxy-\u03b2-methylbutyrate (HMB) stimulates myogenic cell proliferation, differentiation and survival via the MAPK\/ERK and PI3K\/Akt pathways","volume":"1793","author":"Kornasio","year":"2009","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"2021112216472296200_BCJ-2017-0032CC114","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/0008-5472.277.65.1","article-title":"Attenuation of proteasome-induced proteolysis in skeletal muscle by \u03b2-hydroxy-\u03b2-methylbutyrate in cancer-induced muscle loss","volume":"65","author":"Smith","year":"2005","journal-title":"Cancer Res."},{"key":"2021112216472296200_BCJ-2017-0032CC115","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/S0002-9610(02)00823-1","article-title":"Reversal of cancer-related wasting using oral supplementation with a combination of \u03b2-hydroxy-\u03b2-methylbutyrate, arginine, and glutamine","volume":"183","author":"May","year":"2002","journal-title":"Am. J. Surg."},{"key":"2021112216472296200_BCJ-2017-0032CC116","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00520-008-0403-7","article-title":"A randomized, double-blind, placebo-controlled trial of a \u03b2-hydroxyl \u03b2-methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122)","volume":"16","author":"Berk","year":"2008","journal-title":"Support. Care Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC117","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.nut.2013.11.012","article-title":"Comparison of the anticatabolic effects of leucine and Ca-\u03b2-hydroxy-\u03b2-methylbutyrate in experimental models of cancer cachexia","volume":"30","author":"Mirza","year":"2014","journal-title":"Nutrition"},{"key":"2021112216472296200_BCJ-2017-0032CC118","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT01607879, Use of \u03b2-hydroxy-\u03b2-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation, April 20, 2012, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01607879"},{"key":"2021112216472296200_BCJ-2017-0032CC119","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1007\/s00726-013-1592-z","article-title":"\u03b2-hydroxy-\u03b2-methylbutyrate supplementation in health and disease: a systematic review of randomized trials","volume":"45","author":"Molfino","year":"2013","journal-title":"Amino Acids"},{"key":"2021112216472296200_BCJ-2017-0032CC120","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/SPC.0000000000000170","article-title":"The therapeutic potential of exercise to treat cachexia","volume":"9","author":"Lira","year":"2015","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"2021112216472296200_BCJ-2017-0032CC121","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.lfs.2014.11.029","article-title":"Aerobic exercise training as therapy for cardiac and cancer cachexia","volume":"125","author":"Alves","year":"2015","journal-title":"Life Sci."},{"key":"2021112216472296200_BCJ-2017-0032CC122","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.radonc.2013.07.002","article-title":"Progressive resistance training rebuilds lean body mass in head and neck cancer patients after radiotherapy \u2013 results from the randomized DAHANCA 25B trial","volume":"108","author":"L\u00f8nbro","year":"2013","journal-title":"Radiother. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC123","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3138\/ptc.2014-13O","article-title":"Sustainability of outcomes after a randomized crossover trial of resistance exercise for shoulder dysfunction in survivors of head and neck cancer","volume":"67","author":"McNeely","year":"2015","journal-title":"Physiother. Canada"},{"key":"2021112216472296200_BCJ-2017-0032CC124","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.lungcan.2011.05.026","article-title":"Feasibility and preliminary efficacy of progressive resistance exercise training in lung cancer survivors","volume":"75","author":"Peddle-McIntyre","year":"2012","journal-title":"Lung Cancer"},{"key":"2021112216472296200_BCJ-2017-0032CC125","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-007-9638-0","article-title":"Progressive resistance training in breast cancer: a systematic review of clinical trials","volume":"109","author":"Cheema","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"2021112216472296200_BCJ-2017-0032CC126","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.critrevonc.2014.10.014","article-title":"Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach","volume":"94","author":"Muscaritoli","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2021112216472296200_BCJ-2017-0032CC127","unstructured":"Fossen, C. Pre-MENAC study presentation - PRC, NTNU"},{"key":"2021112216472296200_BCJ-2017-0032CC128","unstructured":"ClinicalTrials.gov [internet]. Bethesda (MD): National Library of Medicine (US) Feb 29, 2000 - . Identifier NCT02330926, Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy, December 31, 2014, Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02330926"},{"key":"2021112216472296200_BCJ-2017-0032CC129","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/jco.2014.32.31_suppl.189","article-title":"A combined treatment approach for cachexia and cancer-related anemia in advanced cancer patients: a randomized placebo-controlled trial","volume":"32","author":"Madeddu","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC130","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/SPC.0000000000000241","article-title":"Practical multimodal care for cancer cachexia","volume":"10","author":"Maddocks","year":"2016","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"2021112216472296200_BCJ-2017-0032CC131","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s13539-011-0027-5","article-title":"The cachexia score (CASCO): a new tool for staging cachectic cancer patients","volume":"2","author":"Argil\u00e9s","year":"2011","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC132","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fphys.2017.00092","article-title":"Validation of the CAchexia SCOre (CASCO). staging cancer patients: the use of miniCASCO as a simplified tool","volume":"8","author":"Argil\u00e9s","year":"2017","journal-title":"Front. Physiol."},{"key":"2021112216472296200_BCJ-2017-0032CC133","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"2021112216472296200_BCJ-2017-0032CC134","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jcsm.12005","article-title":"Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients","volume":"6","author":"Stephens","year":"2015","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"2021112216472296200_BCJ-2017-0032CC135","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/jcsm.12083","article-title":"Request for regulatory guidance for cancer cachexia intervention trials","volume":"6","author":"Fearon","year":"2015","journal-title":"J. Cachexia Sarcopenia Muscle"}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/474\/16\/2663\/691842\/bcj-2017-0032c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/474\/16\/2663\/691842\/bcj-2017-0032c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T11:21:51Z","timestamp":1659266511000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/474\/16\/2663\/49631\/Novel-targeted-therapies-for-cancer-cachexia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,27]]},"references-count":135,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017,8,15]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20170032","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,27]]}}}